Beijing Qingda Yinghua Biotechnology

Beijing Qingda Yinghua Biotechnology is a clinical-stage biotechnology company focused on the development of next-generation immune cell therapies for cancer. Established with technical support and intellectual property from Tsinghua University, the company specializes in Chimeric Antigen Receptor T-cell (CAR-T) technologies targeting various hematological and solid malignancies. Their lead programs include CAR-T therapies targeting CD19 and BCMA, which have progressed into clinical trials for lymphoma and myeloma. The company aims to optimize cell manufacturing processes and improve the persistence and safety of engineered cells within the tumor microenvironment. Qingda Yinghua is a significant participant in the Chinese cell therapy sector, operating research and development facilities in Beijing.